Home|Journals|Articles by Year|Audio Abstracts
 

Review Article

J App Pharm Sci. 2024; 14(10): 25-34


Constituents of carbazole alkaloids and anti-cancer properties of extracts, mahanine, isomahanine, mahanimbine, and girinimbine from Bergera koenigii

Eric Wei Chiang Chan, Siu Kuin Wong.




Abstract

The new name of Murraya koenigii (L.) Spreng. is Bergera koenigii L., the Indian curry leaf tree. Constituents of carbazole alkaloids from different plant parts of B. koenigii are compiled. Based on the number of reports, mahanimbine (MNB) and koenimbine are the two most dominant carbazole alkaloids from the leaf of B. koenigii. Carbazole alkaloids selected for review are mahanine (MN), isomahanine (IMN), MNB, and girinimbine (GNB) which are pyranocarbazoles as they possess the pyranocarbazole skeleton. MN, IMN, and MNB have 23 carbons and four methyl groups, while GNB has 18 carbons and three methyl groups. The anti-cancer properties of extracts and carbazole alkaloids from B. koenigii are tabulated with information on cancer types, cancer cell lines, effects, and mechanisms. Other pharmacological properties are briefly mentioned. Findings on the anti-cancer properties of extracts and carbazole alkaloids that will generate interest for further research are included as concluding remarks. Eight areas for future research were suggested.

Key words: Murraya koenigii, Rutaceae, Indian curry leaf, Pyranocarbazoles






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.